UA118851C2 - Способи застосування діамінопіримідинових модуляторів р2х3 та р2х2/3 рецепторів для лікування гострого та підгострого кашлю, позиву до кашлю та хронічного кашлю при респіраторних хворобах - Google Patents

Способи застосування діамінопіримідинових модуляторів р2х3 та р2х2/3 рецепторів для лікування гострого та підгострого кашлю, позиву до кашлю та хронічного кашлю при респіраторних хворобах

Info

Publication number
UA118851C2
UA118851C2 UAA201601740A UAA201601740A UA118851C2 UA 118851 C2 UA118851 C2 UA 118851C2 UA A201601740 A UAA201601740 A UA A201601740A UA A201601740 A UAA201601740 A UA A201601740A UA 118851 C2 UA118851 C2 UA 118851C2
Authority
UA
Ukraine
Prior art keywords
acute
treatment
diaminopyrimidine
sub
chronic cough
Prior art date
Application number
UAA201601740A
Other languages
English (en)
Inventor
Ентоні П. Форд
Брюс Г. МакКарті
Original Assignee
Ефферент Фармасьютікалз Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52480919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA118851(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ефферент Фармасьютікалз Інк. filed Critical Ефферент Фармасьютікалз Інк.
Publication of UA118851C2 publication Critical patent/UA118851C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується лікування гострого, підгострого або хронічного кашлю із застосуванням 5-(2,4-діамінопіримідин-5-ілоксі)-4-ізопропіл-2-метоксибензолсульфонаміду (Сполуки 16) EMBED ISISServer (Сполука 16) або її фармацевтично прийнятної солі.
UAA201601740A 2013-08-23 2014-08-22 Способи застосування діамінопіримідинових модуляторів р2х3 та р2х2/3 рецепторів для лікування гострого та підгострого кашлю, позиву до кашлю та хронічного кашлю при респіраторних хворобах UA118851C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869174P 2013-08-23 2013-08-23
PCT/US2014/052389 WO2015027212A1 (en) 2013-08-23 2014-08-22 Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough

Publications (1)

Publication Number Publication Date
UA118851C2 true UA118851C2 (uk) 2019-03-25

Family

ID=52480919

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201601740A UA118851C2 (uk) 2013-08-23 2014-08-22 Способи застосування діамінопіримідинових модуляторів р2х3 та р2х2/3 рецепторів для лікування гострого та підгострого кашлю, позиву до кашлю та хронічного кашлю при респіраторних хворобах

Country Status (21)

Country Link
US (3) US9284279B2 (uk)
EP (2) EP3865134A1 (uk)
JP (3) JP6546592B2 (uk)
KR (1) KR102196885B1 (uk)
CN (1) CN105682659B (uk)
AU (1) AU2014308606B2 (uk)
CA (1) CA2921395C (uk)
CL (3) CL2016000400A1 (uk)
CR (1) CR20160093A (uk)
HK (1) HK1222126A1 (uk)
IL (1) IL244131B (uk)
MX (1) MX367657B (uk)
MY (1) MY195728A (uk)
NI (1) NI201600029A (uk)
NZ (1) NZ716977A (uk)
PE (1) PE20160431A1 (uk)
PH (1) PH12016500357A1 (uk)
RU (1) RU2650118C2 (uk)
SG (1) SG11201601145RA (uk)
UA (1) UA118851C2 (uk)
WO (1) WO2015027212A1 (uk)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6546592B2 (ja) 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
ES2942711T3 (es) * 2015-09-29 2023-06-06 Afferent Pharmaceuticals Inc Moduladores de los receptores P2X3 y P2X2/3 de diaminopirimidina para su uso en el tratamiento de la tos
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
CA3018180C (en) 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
CN109803724A (zh) 2016-10-07 2019-05-24 瑞思皮万特科学有限责任公司 用于治疗肺纤维化的色甘酸组合物
WO2018111738A1 (en) 2016-12-15 2018-06-21 Afferent Pharmaceuticals, Inc. Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
WO2018118668A1 (en) * 2016-12-20 2018-06-28 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a p2x3 antagonist
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
US11440935B2 (en) 2018-03-15 2022-09-13 Merck Patent Gmbh 3″,5″-dimethoxybenzoyl-3′-amino-3′-deoxy adenosine-5′-triphosphates and pharmaceutical uses thereof
BR112020020549A8 (pt) 2018-04-23 2023-02-07 Msd Werthenstein Biopharma Gmbh Novo processo para síntese de um composto fenoxi diaminopirimidina
CA3100096A1 (en) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MX2020012202A (es) 2018-05-15 2021-01-29 Bayer Ag Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas.
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
WO2020071530A1 (ja) * 2018-10-05 2020-04-09 塩野義製薬株式会社 慢性咳嗽治療用医薬
CA3138235A1 (en) * 2019-04-30 2020-11-05 Beijing Tide Pharmaceutical Co., Ltd. Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof
EP3960179A4 (en) * 2019-04-30 2023-01-25 Beijing Tide Pharmaceutical Co., Ltd. METHOD OF TREATMENT OF COUGH USING A DIAMINOPYRIMIDINE COMPOUND
JP6873534B1 (ja) 2019-09-19 2021-05-19 塩野義製薬株式会社 １，３，５−トリアジン誘導体またはその溶媒和物の結晶およびその製造方法
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725540B1 (en) 2004-03-05 2012-09-12 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2006012639A2 (en) 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
CA2620129C (en) * 2005-09-01 2014-12-23 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4850914B2 (ja) * 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
CN101296907B (zh) * 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
EP1926716B1 (en) 2005-09-01 2011-10-19 F. Hoffmann-La Roche AG Process for synthesis of aryloxy diaminopyrimidines
JP5128603B2 (ja) * 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2013118855A1 (ja) * 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
JP6546592B2 (ja) * 2013-08-23 2019-07-17 アファレント ファーマシューティカルズ インコーポレイテッド 急性、亜急性または慢性の咳を治療するためのジアミノピリミジンｐ２ｘ３およびｐ２ｘ２／３受容体モジュレーター
US9133647B2 (en) * 2013-10-11 2015-09-15 Nexkey, Inc. NFC or BLE based contactless lock with charge monitoring of its energy storage

Also Published As

Publication number Publication date
HK1222126A1 (zh) 2017-06-23
CA2921395A1 (en) 2015-02-26
MX367657B (es) 2019-08-30
JP2023002662A (ja) 2023-01-10
CN105682659A (zh) 2016-06-15
JP7210348B2 (ja) 2023-01-23
JP2016528301A (ja) 2016-09-15
IL244131A0 (en) 2016-04-21
US10206922B2 (en) 2019-02-19
US20160263112A1 (en) 2016-09-15
US9284279B2 (en) 2016-03-15
PE20160431A1 (es) 2016-06-02
AU2014308606A1 (en) 2016-03-10
WO2015027212A1 (en) 2015-02-26
CL2016000400A1 (es) 2017-01-20
CN105682659B (zh) 2019-12-10
JP6546592B2 (ja) 2019-07-17
US20150057299A1 (en) 2015-02-26
SG11201601145RA (en) 2016-03-30
CR20160093A (es) 2016-08-26
US20170326142A1 (en) 2017-11-16
MX2016002289A (es) 2016-09-06
IL244131B (en) 2019-06-30
CL2018002138A1 (es) 2018-10-05
RU2650118C2 (ru) 2018-04-09
AU2014308606B2 (en) 2017-08-03
NI201600029A (es) 2017-09-22
RU2016105581A (ru) 2017-09-28
JP7423725B2 (ja) 2024-01-29
MY195728A (en) 2023-02-07
EP3035932A1 (en) 2016-06-29
KR20160052581A (ko) 2016-05-12
PH12016500357A1 (en) 2016-05-16
EP3035932A4 (en) 2017-01-04
NZ716977A (en) 2017-09-29
US9724346B2 (en) 2017-08-08
CL2018002137A1 (es) 2018-10-05
KR102196885B1 (ko) 2020-12-30
CA2921395C (en) 2022-04-26
JP2019112459A (ja) 2019-07-11
EP3865134A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
PH12016500357A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
PH12019501448A1 (en) Immunomodulator compounds and methods of use
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016005560A (es) Compuestos agonistas triples de glucagon-glp-1-gip.
BR112014020826A2 (pt) moduladores e métodos de uso
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
MY189912A (en) Substituted xanthines and methods of use thereof
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12017500710A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1216641A1 (zh) 用於治療σ受體相關疾病和病症的 -三唑- -胺
MX2016006657A (es) Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
PH12015502820A1 (en) Nanoparticulate formulation comprising a trpa1 antagonist
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.